Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.34 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL930755 | 0.79 | GABRA1 (0.48) | GABRA1GABRB2TSHR | |
| SCHEMBL930890 | 0.74 | TSHR (0.53) | GABRA1GABRB2TSHR | |
| SCHEMBL6313678 | 0.74 | HTR2A (0.35) | MEN1MAPTCYP2C9KMT2ACRHBP | |
| SCHEMBL19925871 | 0.73 | — | — | |
| SCHEMBL36796 | 0.71 | GABRA1 (0.60) | MEN1MAPTCYP2C9KMT2ACRHBP | |
| SCHEMBL2195862 | 0.70 | TYR (0.50) | MAPTGABRA1GABRB2TSHR | |
| SCHEMBL8758494 | 0.68 | MEN1 (0.36) | MEN1MAPTCYP2C9KMT2ACRHBP | |
| SCHEMBL5366216 | 0.67 | GABRA1 (0.48) | GABRA1GABRB2TSHR | |
| SCHEMBL6008290 | 0.67 | EP300 (0.36) | MEN1MAPTCYP2C9KMT2ATSHR | |
| SCHEMBL6320889 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10882819-B2 | Synthesis of novel intermediate(s) for preparing rivastigmine | Cadila Corporate Campus (IN) | 2021-01-05 | — | — | US | disclosed |
| US-20200095195-A1 | SYNTHESIS OF NOVEL INTERMEDIATE(S) FOR PREPARING RIVASTIGMINE | CADILA PHARMACEUTICALS, LTD. (IN) | 2020-03-26 | — | — | US | disclosed |
| CN-103193679-B | The preparation method of rivastigmine intermediate (R)-N-ethyl-N-methylamino formic acid-3-(1-hydroxyethyl) phenyl ester | ZHEJIANG JIUZHOU PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2016-04-06 | — | — | CN | disclosed |
| CN-103193600-B | The preparation method of rivastigmine intermediate | ZHEJIANG JIUZHOU PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2016-04-06 | — | — | CN | disclosed |
| CN-103193679-A | Preparation method of rivastigmine intermediate (R)-N-ethyl-N-methyl carbamic acid-3-(1-hydroxyethyl) phenyl ester | ZHEJIANG JIUZHOU PHARMACEUTICAL TECHNOLOGY CO LTD | 2013-07-10 | — | — | CN | disclosed |
| CN-103193600-A | Method for preparing rivastigmine intermediate | ZHEJIANG JIUZHOU PHARMACEUTICAL TECHNOLOGY CO LTD | 2013-07-10 | — | — | CN | disclosed |
| EP-1939172-B1 | METHOD OF OBTAINING PHENYL CARBAMATES | INTERQUIM SA (ES) | 2012-07-11 | — | — | EP | disclosed |
| EP-1939172-A2 | METHOD OF OBTAINING PHENYL CARBAMATES | Interquim, S.A. (ES) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882819-B2 | Synthesis of novel intermediate(s) for preparing rivastigmine | ACHE, SQLE, BCHE | MEN1 588/4885MAPT 1107/4885CYP2C9 47/4885 |
| US-20200095195-A1 | SYNTHESIS OF NOVEL INTERMEDIATE(S) FOR PREPARING RIVASTIGMINE | ACHE, SQLE, BCHE | MEN1 588/4885MAPT 1107/4885CYP2C9 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.